Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice
Year: 2022
Type: article
Abstract: INTRODUCTION: Lurasidone is an atypical antipsychotic agent approved in the European Union for the treatment of schizophrenia in adults and adolescents (13-17 years). Clinical trials have shown a generally favorable balance between efficacy and tolerability. AREAS COVERED: This paper provides a review and commentary regarding the use of lurasidone in adults and adolescents with schizophrenia. The available information about efficacy, tolerability, dosing, and switching is analyzed, highlighting the strategies that may be most useful in real-world clinical practice. Virtual case studies, designed based on the authors' clinical experience with real-world patients, are provided. EXPERT OPINION: Lurasidone is efficacious in adolescents and adults in a wide range of symptoms of schizophrenia. Choosing the right dose for each patient and combining lurasidone with other medications is key to treatment success. Lurasidone has proven effective both in adolescents and adults in treating the acute phase of schizophrenia and reducing the risk of relapse. It has shown a relatively favorable tolerability profile, with minimal effects on metabolic parameters and prolactin levels.
Institutions: University of Campania "Luigi Vanvitelli", University of Siena, University of Trieste, Azienda sanitaria universitaria Giuliano Isontina, Aziende Socio Sanitarie Territoriale Lodi, Azienda Ospedaliera Sant'Andrea, Sapienza University of Rome, Ospedale Policlinico San Martino, University of Genoa, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, University of Cagliari
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Angelini Pharma
OpenAlex ID: W4309288404